A 2005 meta-analysis suggests that lowering intraocular pressure (lOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) is beneficial in reducing the risk for visual field loss in the long term.
INTRODUCTION
Glaucoma is a common cause of irreversible blindness. Elevated intraocular pressure (lOP) is a major risk factor for glaucoma. lOP reduction (IOPR) is the primary goal of treatments for glaucoma and ocular hypertension (OHT).1,2 A newly published meta-analysis suggests that lowering lOP in patients with OHT or open-angle glaucoma (OAG) is beneficial in reducing the risk for visual field loss in the long term. 3 Prostaglandin analogues are lOP-lowering agents commonly used as first-line treatments of OHT and OAG. 4 Latanoprost, an F 2 u-prostaglandin analogue, became commercially available in 1996. It was associated with greater efficacy in the treatment of OHT compared with timolol in a previously published meta-analysis of data from 17 studies (1491 patients). 5 Travoprost is a topical ocular isopropyl ester prodrug that is hydrolyzed by esterases in the cornea to the biologically active free acid. Travoprost is structurally similar to other F2u-prostaglandin analogues and has a greater affinity for the prostaglandin F receptor than does latanoprost. 6 Three meta-analyses have assessed the efficacy of prostaglandin analogues such as latanoprost and travoprost,7-9 with inconsistent results.
The present meta-analysis compared the efficacy and tolerability of travoprost and latanoprost in the treatment of OHT and OAG.
MATERIALS AND METHODS
This meta-analysis was conducted according to a predetermined protocol using standard systematic review techniques, as outlined by the Cochrane Collaboration (Oxford, United Kingdom).l0
SEARCH STRATEGY
Randomized controlled trials (RCTs), meta-analyses, and systematic reviews published from 1996 to 2008 that compared the effects of travoprost 0.004% and latanoprost 0.005% were identified using a systematic search of the Cochrane Library, MEDLINE, EMBASE, and the Chinese Biomedicine Database. A broad search strategy combined terms related to drugs (including a MeSH search of exp prostaglandins f and synthetic*, and a search of the key words travoprost, Travatan, latanoprost, Xalatan, and prostaglandin*) and diseases (including a MeSH search of exp glaucoma* and exp ocular hypertension*, and a search of the key words glaucoma and ocular hypertension). The original search was conducted in December 2007. Regular alerts every 3 months were established on MEDLINE and EMBASE to capture studies published up to December 31, 2008 . Searches of the Cochrane databases were updated regularly, with the last conducted on issue 4, October 2008.
Google and Yahoo! were searched using the terms travoprost and Travatan up to December 31, 2008 . Web sites of professional associations, such as the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the International Glaucoma Association, and the Association of International Glaucoma Societies, and their associated conference sites were searched for additional information. Trial registries, including ClinicalTrials.gov and the Chinese Clinical Trial Registry, were searched for completed and ongoing trials using the terms travoprost and Travatan. Manufacturers of pharmaceutical agents, including Pfizer Inc. and Alcon Inc., were also contacted for additional materials.
A manual search was performed G.-W.e. and G.-L.X., independently) by checking the reference lists of original reports and review articles, retrieved through the electronic searches, to identifY studies not yet included in the computerized databases.
TRIALS SELECTION
Published and unpublished trials fulfilling the following inclusion criteria were included in the present meta-analysis: randomized clinical trials with adequate institutional review board review and consent processes; trials in patients with OHT or OAG and an elevated lOP (>21 mm Hg) after a washout period; trials that compared travoprost 0.004% and latanoprost 0.005% administered as monotherapy once daily; and;;> 1 of the following end point variables: diurnal mean IOPR from baseline and/or IOPR measured at 9 AM and/or 5 PM. Studies in patients with other types of glaucoma, such as normal-tension glaucoma and chronic angle-closure glaucoma, were excluded, as were those involving no patients with glaucoma; any adjunctive therapy, either topical or systemic, for lowering lOP; medication administered using a nontopical route; administration of either drug at a dose and/or frequency other than that described above; lOP data that could not be extracted; and/or lOP measurements only within 24 hours after baseline.
After completion of the searches, 2 of the authors G.-W.e. and G.-L.X.) independently assessed the titles and abstracts of all obtained reports for a rough judgment of an article's eligibility. The full-text copies of possibly and definitely relevant trials were obtained and assessed by the 2 authors independently according to the definitions in the criteria, which were checked by a third author (R.-L.W.). Only trials meeting the criteria were assessed for methodologic quality. If 2 articles reported on the same study population (duplicate publication), the article that reported the results of the last end point was included, and data that could not be obtained from that publication were obtained from others.
During selection, the authors were masked to the names of the study investigators and their institutions, journal titles, sources of funding, and acknowledgments, as well as the financer of the study, if any. Data were extracted by 2 authors G.-W.e. and G.-L.X.) independently. For each study and treatment, the following data were extracted: authors; year of publication; study design, location, and duration; number of patients; and patients' age, sex, race, type of glaucoma, and lOP measurements. The proportions of patients who withdrew and/or experienced adverse events (AEs) were recorded. Numeric discrepancies between the 2 independent data extractions were resolved after discussion.
OUTCOMES MEASURES
Efficacy was assessed using mean (SD) IOPR measurements (diurnal, 9 AM ± 1 hour, and 5 PM ± 1 hour). Unavailable means were calculated according to the methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Cochrane Collaboration). 10 When SE was reported, SD was calculated as SE x N 1/2 . When the difference in means (MD) and their t values (as obtained from a computer by entering =tinv [P value, Ntreat + N contro1 -2} into any cell in a spreadsheet [Excel, Microsoft Corporation, Redmond, California}) were reported, SD was calculated as MD x r 1 x (N-\reat + N-lcontrol)-1/2. When mean (SD) IOPRs were not available, they were calculated as follows: IOPR = IOPbaseline -IOPendpoint and SD 10PR = (SD\aseline + SD2
. -SD . x SD . )1/2 end POlllt baselllle end POlllt . Tolerability was assessed by considering the overall rates of withdrawal due to AEs and the proportions of patients who experienced AEs.
QUALITATIVE ASSESSMENT
Two of the authors G.-W.e. and G.-L.X.) used standard criteria (allocation concealment, blinding, intent-to-treat [ITT} analysis, and loss to follow-up) to appraise study quality in duplicate and to assess quantitative quality using the ]adad scoring system, as follows ll : allocation concealment, coded as adequate (l point), inadequate or unclear (both, 0 points); masking, coded as double-masked (2 points), single-masked (1 point), or open label (0 points); ITT analysis, coded as used (l point) or not used or unable to assess (both, 0 points); and loss to follow-up, coded as reported (l point) or not reported (0 points). A]adad score <3 = poor quality.
STATISTICAL ANALYSIS
Not all of the trials reported all of the outcomes of interest; therefore, a separate meta-analysis was conducted for each comparison and outcome. The analysis of efficacy data was stratified by duration of treatment. Statistical analysis was performed using RevMan version 4.2.6 (Cochrane Collaboration). Outcomes measures were assessed on an ITT basis, with the ITT population comprising all randomized patients who received :2:1 dose of active treatment and had valid baseline data available. Relative risk (RR) was estimated for dichotomous outcomes. Weighted mean difference (WMD) was calculated for continuous outcomes. The pooled effects ofRR and WMD were combined using a random-effects modeP2 Results were presented with 95% CIs. P < 0.05 was considered statistically significant. To detect publication biases, asymmetry in funnel plots was visually examined.
RESULTS
The flow of the RCTs included in the present analysis is shown in Figure 1 . Of the 1333 studies identified in the initial electronic and manual searches, the full text of 33 articles was reviewed. A total of 22 studies met the criteria for inclusion, with 5 duplicate publications. Therefore, 17 RCTs (1491 patients) were included in the meta-analysis. 13 (1) Studies obtained for full paper review (n = 33)
Excluded (n = 11) No data on intraocular pressure (4) f-----No monotherapy (4) Angle-closure glaucoma (2) No glaucoma patients (1) Eligible studies meeting the criteria 13,14,21,22,26,27; investigators, in 12 studies (71%)13-1 5,20-2 3,25-2 9; and outcomes assessors, in 12 studies (71 %). [13] [14] [15] [19] [20] [21] [22] [25] [26] [27] [28] [29] Data were analyzed using the ITT principle in 6 studies (35%). 13, 15, 17, 21, 22, 27 Funnel plots were considered qualitatively symmetric (Figure 2 ), suggesting the absence of publication bias.
EFFICACY

Diurnal Mean Intraocular Pressure Reduction
Diurnal mean IOPRs are shown in Figure 3 . IOPR values were significant with both study drugs. Travoprost was associated with significantly greater diurnal mean IOPRs compared with latanoprost at 2 weeks and 2 months (WMDs [95% eI} mm Hg:
,: 
AM Intraocular Pressure Reduction
Five trials (748 patients) reported the 9 AM mean IOPR at 2 weeks (travoprost, 7.71 mm Hg; latanoprost, 7.58 mm Hg [Table II}) 
PM Intraocular Pressure Reduction
Three trials (726 patients) reported the 5 PM mean IOPR at 2 weeks (travoprost, 7.72 mm Hg; latanoprost, 6.85 mm Hg)13,17,21; the difference between groups was statistically significant (WMD [95% CI}, 0.87 mm Hg, [0.40 to l.33}) ( Table II) (Table III) . Three patients in the travoprost group discontinued due to conjunctival hyperemia. There were no significant differences between travoprost and latanoprost in the incidence of any reported AEs, including serious ocular AEs (cystoid macular edema, 1/17 [ 
DISCUSSION
The findings from the present meta-analysis suggest that travoprost was as effective as latanoprost in lowering lOP in patients with OHT or OAG, with significantly greater mean diurnal and 5 PM IOPRs found at 2 weeks. lOP lowering has been proven to reduce the risk of glaucomatous progression in patients with glaucoma. A meta-analysis of RCTs revealed that an lOP-lowering strategy delays the progression of visual field deterioration in patients with OHT or manifest glaucoma. 30 Depending on the glaucomatous damage and the presence of other risk factors, the target lOP sometimes has to be chosen such that lOP lowering beyond 35% is necessary,3l From all the choices of lOP-lowering agents, a reasonable r initial approach would be to choose a monotherapy that will get the lOP as low as safely possible in each particular patient. 32 A previously published meta-analysis of 42 articles (9295 patients) reported the IOPRs with bimatoprost (7.81 mm Hg), travoprost (7.69 mm Hg), and latanoprost (6.69 mm Hg).7 These values were comparable to the WMD IOPRs with travoprost (range, 7.10-9.47 mm Hg) and latanoprost (range, 7.09-8.23 mm Hg) at various time points in the present analysis. Li et al 8 analyzed data from 12 RCTs (3048 patients) and reported that the efficacy of travoprost 0.004% was similar to that of bimatoprost 0.03% and latanoprost 0.005%. However, Denis et al 9 analyzed data from 9 RCTs (1318 patients) that compared the efficacy of prostaglandin analogues (eg, travoprost, bimatoprost, and latanoprost) and reported that travoprost and bimatoprost might be more effective than latanoprost for lOP lowering in patients with OHT or OAG. In contrast to those analyses, the present meta-analysis examined RCTs that used direct comparisons between travoprost and latanoprost, and found that these agents were comparable in lowering lOP.
Both travoprost and latanoprost were generally well tolerated. That conjunctival hyperemia was significantly more common with travoprost than with latanoprost might limit its use due to cosmetic concern. However, this AE was mild and resolved without treatment. 33 ,34 Three patients in the travoprost group discontinued due to conjunctival hyperemia.
STRENGTHS
Whereas previously published meta-analyses calculated just 1 IOPR and/or used only 1 postbaseline time point, the present analysis used several IOPR end points (diurnal, 9 AM, and 5 PM) at 2 weeks and 1,2,3,6, and 12 months. To avoid potential heterogeneity based on data pooled from trials of different durations, the analyses of efficacy data were stratified by duration of treatment and each time point was analyzed separately. To avoid acknowledged and covert duplication of data, 2 independent researchers judged the eligibility of articles and extracted data from the eligible articles, with discrepancies resolved using discussion among all of the authors. Only the series of the same patient group at the last end point were included in the present analysis. Asymmetry was explored using funnel plots to detect potential publication biases, and none was found. To further avoid publication bias, multiple databases and Web sites were searched, without trial exclusion based on language.
LIMITATIONS
One limitation of the present analysis was that 4 trials included in the analysis were of poor quality based on ]adad scores. Most of the included trials were of a duration of < 12 months. Pragmatic RCTs with durations> 12 months are needed to assess the long-term efficacy of travoprost in lowering lOP.
CONCLUSIONS
The findings from the present meta-analysis of these 17 RCTs suggest that there were no significant differences between travoprost and latanoprost in IOPR in these patients with OHT or OAG. Both agents were generally well tolerated.
